Business · 04/12/2018Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for EXABLATE Neuro Model 4000 Type 1.0 System Patent Extension
Summary
The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM, a medical device, in accordance with federal regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →